SequelSEC

Caris Life Sciences, Inc. CAI

Services-Medical Laboratories · CIK 0002019410 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$989.60M
Fiscal year ended 2026-06-30
Operating income
$153.26M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$3.87BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$13.70Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity6.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth97.0%90th
FCF margin8.2%82th
R&D / revenue12.5%19th
Operating margin5.6%81th
Current ratio7.85x76th
CapEx / revenue2.0%35th
Long-term debt / equity0.66x43th
Net margin-8.4%57th
SBC / revenue8.6%50th

Caris Life Sciences, Inc. (CAI) reported revenue of $989.60M and net income of $105.14M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Caris Life Sciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

Caris Life Sciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$989.60M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$153.26M
Net income$105.14M
Research & development$117.14M
Weighted-average diluted sharesUnavailable
Pretax income$105.02M
Income tax expense-$111.00K
Diluted EPSUnavailable
Selling, general & administrative$418.96M
General & administrative$234.74M
Selling & marketing$184.22M

Balance

Caris Life Sciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$1.23B
Current assets$1.06B
Total liabilities$637.89M
Current liabilities$191.44M
Total equity incl. NCI$591.73M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$116.89M
Goodwill$19.34M
Long-term debt$392.97M
Accounts payable$85.99M

Cash flow

Caris Life Sciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$168.56M
Capital expendituresUnavailable
Investing cash flow-$144.72M
Financing cash flow-$53.78M
Net change in cash-$29.94M
Stock-based compensation$65.11M
Common dividends paidUnavailable
Common share repurchases$21.45M
Depreciation & amortization$20.76M

Derived

Caris Life Sciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin15.5%
FCF marginUnavailable
SBC / revenue6.6%
Current ratio5.53x
Revenue YoY growth85.4%
Net margin10.6%
R&D / revenue11.8%
CapEx / revenueUnavailable
Long-term debt / equity0.66x
Effective tax rate-0.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CAI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-12View SEC filing

Companies in the same industry

ACON ADVB AMS BDSX BGLC BLLN CDNA CELC CFOR CSTL DGX FCHS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.